Journal
VACCINE
Volume 33, Issue 20, Pages 2307-2315Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2015.03.063
Keywords
Influenza; Long-term protection; Nanoparticle-conjugated M2e; Soluble M2e; Universal vaccine
Categories
Funding
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R21AI099575]
Ask authors/readers for more resources
Influenza virus causes seasonal epidemics and also poses a high risk for pandemics. To develop a broadly cross-protective influenza vaccine we have previously shown that a formulation consisting of the extracellular domain of M2 membrane protein (M2e) immobilized on gold nanoparticles (AuNPs) and soluble CpG as an adjuvant can elicit protective immunity against different influenza A subtypes. The vaccine formulation contains M2e that is immobilized on AuNPs, and an excess amount that is freely dissolved in solution, whose role in inducing protective immunity against virus infection is unclear. Using a mouse model, the current study shows that inclusion of excess soluble M2e antigen along with M2e immobilized on AuNPs is vital for inducing high levels of antibody response, and in providing complete protection against lethal influenza virus challenge. We also show that the vaccine induces long-lasting protection against mortality and morbidity upon lethal challenge with influenza A virus. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available